ABCLAbCellera Biologics Inc

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCelleras antibody...

The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients...

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?